Sam Lubner, MD
Hematology & Oncology · Madison, WINPI 1003838145
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,971 of the $2,256 with a category attached, or 87.3%. Servier Pharmaceuticals LLC accounts for 87.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $1,971 and has fallen 91.9% since, to $160 in 2022.
Across 5 payments — averaging $451.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$2K
- Genentech USA, Inc.$125
- Ipsen Biopharmaceuticals, Inc$89
- Lilly USA, LLC$71
Across 95 payments — averaging $8950.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Agios Pharmaceuticals, Inc.$374K
- E.r. Squibb & Sons, L.L.C.$225K
- Incyte Corporation$116K
- Servier Pharmaceuticals LLC$69K
- AstraZeneca$63K
- Servier Affaires Medicales$2K
- plus $1K from 1 others
What the payments were for
- Speaking & faculty fees$1,97187%
- Food & beverage$1256%
- Education$1607%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 2 | $1,971 |
| Genentech USA, Inc. | 1 | $125 |
| Ipsen Biopharmaceuticals, Inc | 1 | $89 |
| Lilly USA, LLC | 1 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,256 in reported general payments places this provider in the 65th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 46 | $63,233 |
| Oxycodone Hcl | 67 | $1,034 |
| Ondansetron Hcl | 38 | $818 |
| Dexamethasone | 16 | $260 |
| Prochlorperazine Maleate | 22 | $216 |
| Mirtazapine | 12 | $95 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Madison
- Vincent MaMadison$37K
- Priyanka PophaliMadison$32K
- Hamid EmamekhooMadison$23K
- Elisavet PaplomataMadison$21K
- Timothy SchmidtMadison$19K
- Sima Ehsani ChimehMadison$17K
- Kalyan Vara Ganesh NadimintiMadison$17K
- Christos KyriakopoulosMadison$16K
- Matthew BrunnerMadison$15K
- Lyndsey RunaasMadison$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.